Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2009

View Archived Issues

General Electric claims VMAT2 ligands as imaging agents for the diagnosis of diabetes

Achaogen describes novel aminoglycoside analogues for the treatment of bacterial infections

Rapamycin delays aging in mice

APPRAISE details risk-benefit profile of apixaban in acute coronary syndrome patients

DMCs recommend continuation of PAION's phase IIa and phase Ib studies of CNS-7065

ImmunoVaccine licenses cancer antigens from Immunotope

Capstone completes enrollment in first of two phase II trials of AZX-100 in keloid scarring

FDA issues complete response letter for Watson's NDA for 24-week Trelstar

Array files IND with the FDA to initiate phase I trial of ARRY-162 in cancer

Cornerstone submitted regulatory filing with FDA for antitussive CRTX-067

Cytochroma initiates pharmacokinetic study of CTAP-101 in stage 3 or 4 CKD patients

Merck Serono receives Japanese approval for Gonal-f for ovulation induction in infertile women

Interleukin-7 enhances vaccine-induced antitumor responses in vivo

EnVivo Pharmaceuticals introduces gamma-secretase inhibitors at ICAD

FDA committee reports negative opinion on trabectedin in ovarian cancer

FDA grants second orphan drug designation to Axentis' Fluidosomes in cystic fibrosis

NICE recommends use of Basilea's Toctino for severe chronic hand eczema

FDA committee reports negative opinion on Doxil in breast cancer

Baxter and Halozyme complete enrollment in phase III trial of Gammagard Liquid

Acrux completes phase III trial of testosterone therapy Axiron

Ipsen reports results from phase I and phase IIa clinical studies of BIM23A-760

Actelion reports phase II data for PGI2 receptor agonist in PAH

BSI-201 enters phase III trials for metastatic triple-negative breast cancer

FDA lifts partial clinical hold on Genmab's zalutumumab studies

Cerebrolysin improves clinical outcomes as add-on therapy in mild AD and vascular dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...